Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $66.5752W HIGH $219.04
Volume
2.58 M
Value Traded
85.71 M
Short % Float
3.89%
Days to Cover
3.7
+15.01%Week
+30.59%1 Month
+33.43%3 Month
+88.76%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
16.14 B
EPS (TTM)
7.43
P/E Ratio
28.44
Ent. Value
11.22 B
Total Shares
76.33 M
Float Shares
76.35 M
Insiders
1.05%
Institutions
104.81%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ICLR Catalyst Timeline
Dated clinical, regulatory and corporate events for Icon Plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Icon Plc
267Total events
1Upcoming
55Tier-1 (high impact)
2007 to 2027Coverage
Event history 50
●Corporate ApprovalCorporate
Board approved increase in share buyback authorization to total $750.0 million
●Debt Royalty FinancingCorporate
Completed $2.15 billion investment grade bond issuance and repaid term loan, May 2027 notes and bridge facility
▲Partnership / LicenseCorporate
Multi-year collaboration with Anthropic to bring Claude AI to clinical trials
●Equity OfferingCorporate
$400.0 million of stock repurchased in Q3 2026 at average price of $170 per share
▲Partnership / LicenseCorporate
ICON selects Microsoft as preferred technology partner for AI-enabled clinical development
◆Oral PresentationPresentation
ICON plc presents at 42nd Annual J.P. Morgan Healthcare Conference
◆Oral PresentationPresentation
ICON plc CFO to present at Jefferies London Healthcare Conference
▲Quarterly UpdateCorporate
ICON reports Q2 2023 results with revenue of $2,020.3M and adjusted EPS of $3.11
◆Oral PresentationPresentation
CFO Brendan Brennan attends UBS Healthcare Services Conference
◆Oral PresentationPresentation
CEO Dr. Steve Cutler presents at William Blair 43rd Annual Growth Stock Conference
◆Oral PresentationPresentation
ICON plc presentation at 41st Annual J.P. Morgan Healthcare Conference
◆Oral PresentationPresentation
ICON plc CFO to present at 2022 Evercore ISI HealthCONx Conference
▲Quarterly UpdateCorporate
ICON reports Q3 2022 results with revenue of $1,942.4M and adjusted EPS of $3.00
●Quarterly UpdateCorporate
Revised FY2022 revenue guidance to $7,690-$7,810M and adjusted EPS guidance to $11.65-$11.85
◆Oral PresentationPresentation
ICON plc CFO presents at H.C. Wainwright Global Investment Conference
◆Oral PresentationPresentation
ICON plc CFO to present at BofA Securities 2022 Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How ICLR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 82%
Mid Cap(rank 539 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ICLR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lyons EmerOfficer (Chief Accounting Officer) | Sell | -42 1,220 held | $180.54 | 10/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ICLR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EAGLE HEALTH INVESTMENTS LP | 8.9 % (29 %) | 53.53 M | 308.14 K | -14.05% ( -50.36 K) |
ICLR Institutional Ownership Trends
ICLR Short Interest
Shares sold short, counted twice a month.
3.89%
Short % of Float
of tradable shares sold short
3.0M
Shares Sold Short
+6.0% vs prior count
3.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
799.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ICLR ranks across every disease it competes in
Competitive Position is a premium feature
See how ICLR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialICLR News
-ICLR
Oct 27, 2026▲ +17%on this news
ICON Reports Third Quarter 2026 Results
ICON plc reported strong third-quarter results with net business wins of $3,150 million and revenue of $2,024.8 million. The adjusted net income rose to $205.8 million, reflecting a 3.9% increase from the previous quarter. However, revenue showed a 2.9% decrease year-over-year, and adjusted EBITDA fell by 13.1%. The company remains focused on disciplined capital allocation and strategic investments.
Read more →-ICLR
Oct 8, 2026ICON Schedules Third Quarter 2026 Earnings Conference Call
ICON plc announced it will release its financial results for Q3 2026 after market close on October 27, 2026. A conference call and webcast to discuss these results is set for October 28, 2026, at 8:00 AM ET. Investors can find updates and access the webcast on the company's website.
Read more →-ICLR
Aug 20, 2026ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability
ICON plc released its 2025 ESG report, highlighting sustainability gains and clinical support. The company earned an EcoVadis Platinum Medal and improved its CDP score. ICON backed 1,370 studies involving 411,400 patients, aiding 25 drug approvals. The firm also reduced greenhouse gas emissions by 73.56% against its 2019 baseline.
Read more →-ICLR
Aug 6, 2026ICON Announces Pricing of USD 2.15 Billion Notes
ICON plc announced the pricing of $2.15 billion in senior unsecured notes. The offering includes three tranches with varying due dates and interest rates. Proceeds will be used to repay existing borrowings and redeem outstanding notes, enhancing the company's financial stability. The offering is set to close on August 13, 2026.
Read more →-ICLR
Aug 4, 2026ICON Announces Private Offering of Notes
ICON plc announced a private offering of senior notes through its subsidiary, ICON Investments Six Designated Activity Company. The proceeds will be used to repay existing debts, including a bridge facility and term loans. The offering is subject to market conditions and there is no guarantee it will close successfully.
Read more →-ICLR
Jul 31, 2026ICON Announces Results of Annual General Meeting
ICON plc held its Annual General Meeting on July 31, 2026, where all proposed resolutions were approved by shareholders. Key votes included the re-election of board members and the authorization of share allotments. The meeting demonstrated strong shareholder engagement and support for the company's governance.
Read more →-ICLR
Jul 29, 2026▼ -7.1%on this newsshared move
ICON Reports Second Quarter 2026 Results
ICON plc reported its second quarter 2026 results, showing a revenue of $2,063.5 million, a 1.4% increase from Q1 2026. Adjusted EBITDA was $327.2 million, reflecting a 3.0% rise. The company reaffirmed its 2026 financial guidance, expecting revenue between $7,850 million and $8,150 million. However, adjusted EBITDA decreased by 21.7% compared to the previous year.
Read more →-ICLR
Jul 28, 2026▲ +6.8%on this news
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials
ICON plc has announced a multi-year partnership with Anthropic to integrate AI capabilities into the clinical trial process. This collaboration aims to enhance ICON's digital innovation and AI strategy by utilizing Anthropic's advanced technologies. The partnership is expected to streamline and accelerate various aspects of clinical trials.
Read more →-ICLR
Jul 22, 2026ICON Schedules Second Quarter 2026 Earnings Conference Call
ICON plc announced it will release its financial results for Q2 2026 on July 29, 2026. A conference call is scheduled for July 30, 2026, at 8:00 am ET to discuss these results. The company emphasizes its leadership in clinical research and plans to provide a webcast replay after the call.
Read more →-ICLR
Jun 23, 2026▲ +10.9%on this news· ran to +21% by day 3
ICON Reports First Quarter 2026 Results
ICON plc reported its Q1 2026 financial results, showing a revenue of $2,034 million, a slight increase from Q1 2025. The company achieved net business wins of $2,880 million and a book-to-bill ratio of 1.42. However, GAAP net income and adjusted EBITDA saw declines compared to the previous year. ICON reaffirmed its full-year guidance for 2026.
Read more →-ICLR
Jun 22, 2026ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development
ICON has selected Microsoft as its preferred technology partner to enhance AI-enabled clinical development. This partnership is expected to leverage Microsoft's advanced technology to improve the efficiency and effectiveness of clinical trials. The collaboration aims to innovate and streamline processes within the clinical development landscape.
Read more →-ICLR
May 28, 2026▲ +15.5%on this news
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
ICON plc reported its financial results for Q4 and full year 2025, highlighting strong net bookings and a positive demand environment. The Audit Committee concluded its investigation into accounting practices, identifying material weaknesses in internal controls. Despite a decrease in earnings per share, ICON anticipates sustainable growth through strategic investments and partnerships.
Read more →-ICLR
May 13, 2026ICON expands US early phase research capabilities with new clinic and outpatient centres
ICON has announced the expansion of its early phase research capabilities in the US by opening new clinic and outpatient centers. This strategic move aims to enhance their service offerings and cater to the growing demand for early phase clinical trials. The expansion reflects ICON's commitment to advancing research in the biopharma sector.
Read more →-ICLR
Feb 12, 2026▼ -39.9%on this news
ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices
ICON plc announced the timing for its fourth quarter and full year 2025 earnings results, expected by April 30, 2026. The company is undergoing an internal investigation into its accounting practices, focusing on revenue recognition from 2023 to 2025. Preliminary findings suggest minor overstatements in revenue, and the company has withdrawn its financial guidance for 2025.
Read more →-ICLR
Jan 27, 2026ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership
ICON plc has announced the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois, enhancing its Accellacare Site Network's oncology research capabilities. This partnership aims to improve patient access to innovative cancer treatments and address recruitment challenges in oncology trials. The institute features a team of specialized oncologists and surgical specialists.
Read more →-ICLR
Jan 7, 2026ICON plc update on issuance of full-year 2026 guidance
ICON plc has announced its intention to issue full-year 2026 guidance alongside the fourth quarter and full-year 2025 results. This decision follows prior updates on the timing of the guidance issuance. The announcement contains forward-looking statements that are based on current expectations and subject to various risks and uncertainties, which may lead to actual results differing from those projected. Investors are advised to exercise caution regarding these statements.
Read more →-ICLR
Mar 3, 2025ICON plc Provides Update on Vaccine Study
ICON plc announced a delay in their large-scale next generation COVID vaccine study by 90 days, which will impact their revenue for the first half of 2025. Despite this setback, the company maintains its financial guidance for the full year of 2025. The delay was highlighted during an earnings call, indicating ongoing challenges with the study's timeline. The situation emphasizes the uncertainties surrounding clinical studies and their implications on financial performance.
Read more →-ICLR
Apr 25, 2024Document THIRD AMENDMENT TO CREDIT AGREEMENT This THIRD AMENDMENT to the Credit Agreement referred to below, dated as of
ICON Luxembourg S.R.L. and its subsidiaries have executed a third amendment to their Credit Agreement, enabling them to refinance existing term loans. This amendment allows for up to $2.38 billion in Repriced Lux Term Loans and approximately $593 million in Repriced U.S. Term Loans. The refinancing aims to consolidate their financial position while reaffirming obligations to lenders. The amendment underscores a collaborative effort between the company and various financial institutions to enhance financial stability.
Read more →-ICLR
Jan 30, 2024ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call
ICON plc has announced the schedule for its fourth quarter and full year 2023 earnings conference call, set for February 22, 2024. The financial results will be disclosed after market closure on February 21, 2024. This announcement underscores ICON's commitment to transparency with its stakeholders. The company is poised to share insights and updates on its performance alongside future expectations amidst market uncertainties.
Read more →-ICLR
Jan 9, 2024ICON Issues Financial Guidance for Full Year 2024 Highlights Full Year 2024 Revenue guidance in the range of $8,400 - $8,800 million, representing growth of 3.2% - 8.1% over Full Year 2023 Revenue guidance midpoint. Full
ICON plc released its financial guidance for the full year of 2024, projecting revenue between $8,400 million to $8,800 million, reflecting a growth rate of 3.2% to 8.1% over the previous year. Additionally, the company estimates adjusted earnings per share to range from $14.50 to $15.30, indicating an anticipated growth of 13.5% to 19.8% compared to 2023. CEO Dr. Steve Cutler emphasized the strengthened market position of ICON as a leading provider of clinical development services, attributing growth to increased operational efficiency and innovative tools in clinical research. Despite prevailing macroeconomic challenges, ICON's outlook remains positive for 2024.
Read more →About Icon Plc
BIOPHARMAWATCH ELITE PLUS
Trade the next ICLR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime